Identification

Name
Ciprofloxacin
Accession Number
DB00537  (APRD00424, EXPT00999)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ciprofloxacin is a broad-spectrum antimicrobial carboxyfluoroquinoline.The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.

Structure
Thumb
Synonyms
  • 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
  • 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  • 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
  • Ciprofloxacine
  • Ciprofloxacino
  • Ciprofloxacinum
External IDs
BAY Q 3939 / BAY-Q-3939 / BAYQ3939 / J01MA02
Product Ingredients
IngredientUNIICASInChI Key
Ciprofloxacin hydrochloride0MP32MFP6C93107-08-5DIOIOSKKIYDRIQ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act CiprofloxacinTablet500 mgOralTeva2004-02-18Not applicableCanada
Act CiprofloxacinTablet250 mgOralTeva2004-02-18Not applicableCanada
Act CiprofloxacinTablet750 mgOralTeva2004-02-18Not applicableCanada
CetraxalSolution / drops.5 mg/.25mLAuricular (otic)Wraser Llc2009-05-14Not applicableUs
CiloxanOintment0.3 %OphthalmicNovartis1998-10-07Not applicableCanada
CiloxanSolution / drops3 mg/mLOphthalmicAlcon, Inc.1991-01-15Not applicableUs
CiloxanSolution / drops3 mg/mLOphthalmicRemedy Repack2018-05-30Not applicableUs
CiloxanSolution0.3 %OphthalmicNovartis1992-12-31Not applicableCanada
CiloxanSolution3.5 mg/mLOphthalmicPhysicians Total Care, Inc.1995-07-10Not applicableUs
CiloxanOintment3 mg/gOphthalmicAlcon, Inc.1998-06-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ciprofloxSolution0.3 %OphthalmicApotex Corporation2005-09-14Not applicableCanada
Apo-ciprofloxTablet500 mgOralApotex Corporation2004-02-09Not applicableCanada
Apo-ciprofloxTablet250 mgOralApotex Corporation2004-02-09Not applicableCanada
Apo-ciprofloxTablet750 mgOralApotex Corporation2004-02-09Not applicableCanada
Auro-ciprofloxacinTablet500 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-ciprofloxacinTablet250 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-ciprofloxacinTablet750 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Bio-ciprofloxacinTablet500 mgOralBiomed Pharma2016-06-17Not applicableCanada
CiprofloxacinTablet500 mg/1OralMesource Pharmaceuticals2004-09-10Not applicableUs
CiprofloxacinTablet250 mg/1OralClinical Solutions Wholsesale2004-09-102017-11-30Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CiproCiprofloxacin (452.2 mg/1) + Ciprofloxacin hydrochloride (574.9 mg/1)Tablet, film coated, extended releaseOralBayer2012-10-01Not applicableUs
CiproCiprofloxacin hydrochloride (2 mg/1mL) + Benzyl alcohol (9 mg/1mL) + Hydrocortisone (10 mg/1mL)SuspensionAuricular (otic)Physicians Total Care, Inc.2009-02-12Not applicableUs
CiproCiprofloxacin (212.6 mg/1) + Ciprofloxacin hydrochloride (287.5 mg/1)Tablet, film coated, extended releaseOralBayer2012-10-01Not applicableUs
CiproCiprofloxacin (452.2 mg/1) + Ciprofloxacin hydrochloride (574.9 mg/1)Tablet, film coated, extended releaseOralBayer2012-10-01Not applicableUs
CiproCiprofloxacin (212.6 mg/1) + Ciprofloxacin hydrochloride (287.5 mg/1)Tablet, film coated, extended releaseOralBayer2012-10-01Not applicableUs
Cipro HCCiprofloxacin hydrochloride (2 mg/mL) + Hydrocortisone (10 mg/mL)SuspensionAuricular (otic)Alcon, Inc.1999-03-15Not applicableUs
Cipro HCCiprofloxacin hydrochloride (2 mg/mL) + Hydrocortisone (10 mg/mL)SuspensionAuricular (otic)A S Medication Solutions1999-03-152017-06-20Us
Cipro HCCiprofloxacin (2 mg/mL) + Benzyl alcohol (9 mg/mL) + Hydrocortisone (10 mg/mL)SuspensionAuricular (otic)Stat Rx USA1998-02-102018-02-08Us
Cipro HC Otic SuspensionCiprofloxacin (2 mg) + Hydrocortisone (10 mg)SuspensionAuricular (otic)Alcon, Inc.1999-06-222008-12-08Canada
CiprodexCiprofloxacin hydrochloride (3 mg/mL) + Dexamethasone (1 mg/mL)SuspensionAuricular (otic)Physicians Total Care, Inc.2004-09-21Not applicableUs
International/Other Brands
Bacquinor / Baycip / Ciflox / Cifloxin / Ciprinol / Ciprobay / Ciprocinol / Ciprodar / Ciproxan / Ciproxin / Flociprin / Proquin
Categories
UNII
5E8K9I0O4U
CAS number
85721-33-1
Weight
Average: 331.3415
Monoisotopic: 331.133219662
Chemical Formula
C17H18FN3O3
InChI Key
MYSWGUAQZAJSOK-UHFFFAOYSA-N
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
IUPAC Name
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
SMILES
OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O

Pharmacology

Indication

For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).

Associated Conditions
Pharmacodynamics

Ciprofloxacin is a broad-spectrum antiinfective agent of the fluoroquinolone class. Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.

Mechanism of action

The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.

TargetActionsOrganism
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UDNA topoisomerase 2-alpha
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
UDNA gyrase subunit ANot AvailableEscherichia coli (strain K12)
UDNA topoisomerase 4 subunit ANot AvailableStaphylococcus aureus
UDNA topoisomerase 4 subunit BNot AvailableBacillus subtilis (strain 168)
UDNA gyrase subunit ANot AvailableBacillus subtilis (strain 168)
UMultidrug resistance protein MdtKNot AvailableEscherichia coli
UGyrase ANot AvailableMycobacterium tuberculosis
UDNA gyrase subunit ANot AvailableStaphylococcus aureus
Absorption

Rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.

Volume of distribution
Not Available
Protein binding

20 to 40%

Metabolism

Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.

Route of elimination

Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug.

Half life

4 hours

Clearance
  • Renal cl=300 mL/min
Toxicity

The major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Ciprofloxacin.Experimental
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Ciprofloxacin.Experimental, Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Ciprofloxacin.Investigational
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Ciprofloxacin.Experimental
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Ciprofloxacin.Experimental
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Ciprofloxacin.Investigational
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be increased when it is combined with Ciprofloxacin.Experimental
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Ciprofloxacin.Experimental
8-azaguanineThe serum concentration of 8-azaguanine can be increased when it is combined with Ciprofloxacin.Experimental
8-chlorotheophyllineThe serum concentration of 8-chlorotheophylline can be increased when it is combined with Ciprofloxacin.Approved
9-DeazaguanineThe serum concentration of 9-Deazaguanine can be increased when it is combined with Ciprofloxacin.Experimental
9-MethylguanineThe serum concentration of 9-Methylguanine can be increased when it is combined with Ciprofloxacin.Experimental
AbemaciclibThe serum concentration of Ciprofloxacin can be increased when it is combined with Abemaciclib.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Abexinostat.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Ciprofloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
AcefyllineThe serum concentration of Acefylline can be increased when it is combined with Ciprofloxacin.Experimental
AcemetacinAcemetacin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Experimental, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ciprofloxacin.Approved, Investigational
AceprometazineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ciprofloxacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Ciprofloxacin.Approved, Investigational, Withdrawn
Acetylcysteine zincAcetylcysteine zinc can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ciprofloxacin.Approved
AcyclovirThe serum concentration of Acyclovir can be increased when it is combined with Ciprofloxacin.Approved
AfatinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Afatinib.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Ciprofloxacin.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ciprofloxacin.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Ciprofloxacin.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Ciprofloxacin.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of tendinopathy can be increased when Alclometasone is combined with Ciprofloxacin.Approved
AldosteroneThe risk or severity of tendinopathy can be increased when Aldosterone is combined with Ciprofloxacin.Experimental, Investigational
AlectinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Alectinib.Approved, Investigational
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ciprofloxacin.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ciprofloxacin.Approved, Vet Approved
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Ciprofloxacin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Ciprofloxacin.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Aluminium clofibrate.Experimental
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Ciprofloxacin.Approved
AmcinonideThe risk or severity of tendinopathy can be increased when Amcinonide is combined with Ciprofloxacin.Approved
AMG-222The therapeutic efficacy of AMG-222 can be increased when used in combination with Ciprofloxacin.Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Amifampridine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ciprofloxacin.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ciprofloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ciprofloxacin.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ciprofloxacin.Approved
AmsacrineThe serum concentration of Ciprofloxacin can be increased when it is combined with Amsacrine.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be increased when used in combination with Ciprofloxacin.Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Anagrelide.Approved
AnnamycinThe serum concentration of Ciprofloxacin can be increased when it is combined with Annamycin.Investigational
AntazolineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Antazoline.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ciprofloxacin.Approved, Investigational
AntrafenineAntrafenine may increase the neuroexcitatory activities of Ciprofloxacin.Approved
ApalutamideThe serum concentration of Ciprofloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ciprofloxacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Ciprofloxacin.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ciprofloxacin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Ciprofloxacin.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Ciprofloxacin.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Ciprofloxacin.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ciprofloxacin.Approved
AtorvastatinThe serum concentration of Ciprofloxacin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Ciprofloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Ciprofloxacin.Approved
AzathioprineThe serum concentration of Azathioprine can be increased when it is combined with Ciprofloxacin.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Ciprofloxacin.Approved
Azilsartan medoxomilThe risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Ciprofloxacin.Approved, Investigational
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Ciprofloxacin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ciprofloxacin.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Ciprofloxacin.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ciprofloxacin.Approved
Bafilomycin A1The serum concentration of Ciprofloxacin can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Ciprofloxacin can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be increased when used in combination with Ciprofloxacin.Investigational
BalsalazideBalsalazide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
BamifyllineThe serum concentration of Bamifylline can be increased when it is combined with Ciprofloxacin.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ciprofloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Ciprofloxacin.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Ciprofloxacin.Investigational
BenazeprilThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Ciprofloxacin.Approved, Investigational
BenazeprilatThe risk or severity of hyperkalemia can be increased when Benazeprilat is combined with Ciprofloxacin.Experimental
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
BenfluorexThe therapeutic efficacy of Benfluorex can be increased when used in combination with Ciprofloxacin.Investigational, Withdrawn
BenorilateBenorilate may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ciprofloxacin.Approved
BenzquinamideThe serum concentration of Ciprofloxacin can be increased when it is combined with Benzquinamide.Withdrawn
BenzydamineThe metabolism of Benzydamine can be decreased when combined with Ciprofloxacin.Approved
Benzyl alcoholThe serum concentration of Ciprofloxacin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of tendinopathy can be increased when Betamethasone is combined with Ciprofloxacin.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Ciprofloxacin.Approved, Investigational
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Bezafibrate.Approved, Investigational
BicalutamideThe serum concentration of Ciprofloxacin can be increased when it is combined with Bicalutamide.Approved
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Ciprofloxacin.Approved, Investigational
Biricodar dicitrateThe serum concentration of Ciprofloxacin can be increased when it is combined with Biricodar dicitrate.Investigational
BoceprevirThe serum concentration of Ciprofloxacin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ciprofloxacin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin.Approved
Brefeldin AThe serum concentration of Ciprofloxacin can be increased when it is combined with Brefeldin A.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Ciprofloxacin.Approved, Illicit, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved
BromocriptineThe therapeutic efficacy of Bromocriptine can be increased when used in combination with Ciprofloxacin.Approved, Investigational
BromotheophyllineThe serum concentration of Bromotheophylline can be increased when it is combined with Ciprofloxacin.Approved
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ciprofloxacin.Approved
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Ciprofloxacin.Approved
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Ciprofloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be increased when used in combination with Ciprofloxacin.Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Ciprofloxacin.Experimental, Investigational
BufyllineThe serum concentration of Bufylline can be increased when it is combined with Ciprofloxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Ciprofloxacin.Approved, Investigational
BuprenorphineThe serum concentration of Ciprofloxacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Ciprofloxacin.Approved, Investigational
BuspironeThe serum concentration of Ciprofloxacin can be increased when it is combined with Buspirone.Approved, Investigational
ButriptylineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Butriptyline.Approved
CabazitaxelThe serum concentration of Ciprofloxacin can be increased when it is combined with Cabazitaxel.Approved
CafedrineThe serum concentration of Cafedrine can be increased when it is combined with Ciprofloxacin.Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ciprofloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.Approved
CandesartanThe risk or severity of hyperkalemia can be increased when Candesartan is combined with Ciprofloxacin.Experimental
Candesartan cilexetilThe risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Ciprofloxacin.Approved
CaptoprilThe risk or severity of hyperkalemia can be increased when Captopril is combined with Ciprofloxacin.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Ciprofloxacin.Experimental, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be increased when used in combination with Ciprofloxacin.Experimental
CarmegliptinThe therapeutic efficacy of Carmegliptin can be increased when used in combination with Ciprofloxacin.Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Ciprofloxacin.Approved, Investigational
CefoperazoneThe serum concentration of Ciprofloxacin can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Ciprofloxacin can be increased when it is combined with Ceftriaxone.Approved
CelecoxibCelecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CeritinibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ceritinib.Approved
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Cerivastatin.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ciprofloxacin.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ciprofloxacin.Approved
ChloroformThe serum concentration of Ciprofloxacin can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ciprofloxacin.Approved, Investigational, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Ciprofloxacin.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Ciprofloxacin.Approved
CiclesonideThe risk or severity of tendinopathy can be increased when Ciclesonide is combined with Ciprofloxacin.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Ciprofloxacin.Experimental
CilazaprilThe risk or severity of hyperkalemia can be increased when Cilazapril is combined with Ciprofloxacin.Approved
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Ciprofloxacin.Approved, Investigational
CimicoxibCimicoxib may increase the neuroexcitatory activities of Ciprofloxacin.Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ciprofloxacin.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ciprofibrate.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of tendinopathy can be increased when Clobetasol is combined with Ciprofloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of tendinopathy can be increased when Clobetasol propionate is combined with Ciprofloxacin.Approved
ClobetasoneThe risk or severity of tendinopathy can be increased when Clobetasone is combined with Ciprofloxacin.Approved
ClocortoloneThe risk or severity of tendinopathy can be increased when Clocortolone is combined with Ciprofloxacin.Approved
ClofazimineThe serum concentration of Ciprofloxacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Clofibride.Experimental
ClomipramineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Ciprofloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Ciprofloxacin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ciprofloxacin.Approved
CloprednolThe risk or severity of tendinopathy can be increased when Cloprednol is combined with Ciprofloxacin.Experimental
ClorindioneThe therapeutic efficacy of Clorindione can be increased when used in combination with Ciprofloxacin.Experimental
ClozapineCiprofloxacin may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Ciprofloxacin can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Ciprofloxacin can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Ciprofloxacin can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Ciprofloxacin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Ciprofloxacin.Approved
CorticotropinThe risk or severity of tendinopathy can be increased when Corticotropin is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of tendinopathy can be increased when Cortisone acetate is combined with Ciprofloxacin.Approved, Investigational
CortivazolThe risk or severity of tendinopathy can be increased when Cortivazol is combined with Ciprofloxacin.Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Ciprofloxacin.Investigational
CurcuminThe serum concentration of Ciprofloxacin can be increased when it is combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ciprofloxacin.Approved
CyclosporineThe serum concentration of Ciprofloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ciprofloxacin.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ciprofloxacin.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Ciprofloxacin.Approved, Investigational
DaclatasvirThe serum concentration of Ciprofloxacin can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dactinomycin.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ciprofloxacin.Approved
DasatinibThe risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ciprofloxacin.Approved, Investigational
DaunorubicinThe serum concentration of Ciprofloxacin can be increased when it is combined with Daunorubicin.Approved
DeflazacortThe risk or severity of tendinopathy can be increased when Deflazacort is combined with Ciprofloxacin.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Ciprofloxacin.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Delamanid.Approved, Investigational
DelaprilThe risk or severity of hyperkalemia can be increased when Delapril is combined with Ciprofloxacin.Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Ciprofloxacin.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Ciprofloxacin.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Desloratadine.Approved, Investigational
DesmethylsertralineThe serum concentration of Ciprofloxacin can be increased when it is combined with Desmethylsertraline.Experimental
DesonideThe risk or severity of tendinopathy can be increased when Desonide is combined with Ciprofloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of tendinopathy can be increased when Desoximetasone is combined with Ciprofloxacin.Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of tendinopathy can be increased when Dexamethasone isonicotinate is combined with Ciprofloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dexchlorpheniramine maleate.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ciprofloxacin.Approved, Illicit, Investigational, Withdrawn
DexibuprofenDexibuprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
DexketoprofenDexketoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
DexniguldipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Ciprofloxacin can be increased when it is combined with Dexverapamil.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ciprofloxacin.Approved, Vet Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Ciprofloxacin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Diethyl etherThe serum concentration of Ciprofloxacin can be increased when it is combined with Diethyl ether.Experimental
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
DiflorasoneThe risk or severity of tendinopathy can be increased when Diflorasone is combined with Ciprofloxacin.Approved
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Ciprofloxacin.Vet Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of tendinopathy can be increased when Difluocortolone is combined with Ciprofloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of tendinopathy can be increased when Difluprednate is combined with Ciprofloxacin.Approved
DihydralazineThe metabolism of Dihydralazine can be decreased when combined with Ciprofloxacin.Approved, Investigational
DihydroergotamineThe serum concentration of Ciprofloxacin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Ciprofloxacin can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dimenhydrinate.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Ciprofloxacin.Approved
DiphenadioneThe therapeutic efficacy of Diphenadione can be increased when used in combination with Ciprofloxacin.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ciprofloxacin.Approved, Investigational
DipyridamoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Disopyramide.Approved
Ditiocarb ZincDitiocarb Zinc can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DofequidarThe serum concentration of Ciprofloxacin can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Ciprofloxacin.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ciprofloxacin.Approved
DovitinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Ciprofloxacin can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Ciprofloxacin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Ciprofloxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ciprofloxacin.Approved, Vet Approved
DronabinolThe serum concentration of Ciprofloxacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Ciprofloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Ciprofloxacin.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be increased when used in combination with Ciprofloxacin.Investigational
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Ciprofloxacin.Approved, Investigational
EconazoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Econazole.Approved
ElacridarThe serum concentration of Ciprofloxacin can be increased when it is combined with Elacridar.Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Eliglustat.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Ciprofloxacin.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Emedastine.Approved
EmopamilThe serum concentration of Ciprofloxacin can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.Approved
EnalaprilThe risk or severity of hyperkalemia can be increased when Enalapril is combined with Ciprofloxacin.Approved, Vet Approved
EnalaprilatThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Ciprofloxacin.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Ciprofloxacin.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be increased when used in combination with Ciprofloxacin.Experimental
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ciprofloxacin.Approved, Investigational
EntecavirThe serum concentration of Entecavir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Ciprofloxacin can be increased when it is combined with Enzalutamide.Approved
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Ciprofloxacin.Approved, Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Ciprofloxacin.Approved
EprosartanThe risk or severity of hyperkalemia can be increased when Eprosartan is combined with Ciprofloxacin.Approved
ErgonovineThe serum concentration of Ciprofloxacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ciprofloxacin can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Ciprofloxacin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Escitalopram.Approved, Investigational
EsomeprazoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Ciprofloxacin can be increased when it is combined with Estramustine.Approved, Investigational
EstroneThe metabolism of Estrone can be decreased when combined with Ciprofloxacin.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ciprofloxacin.Approved
EtamiphyllineThe serum concentration of Etamiphylline can be increased when it is combined with Ciprofloxacin.Experimental
EthanolThe metabolism of Ethanol can be decreased when combined with Ciprofloxacin.Approved
EthenzamideEthenzamide may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Ciprofloxacin.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Etofibrate.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Ciprofloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
EvogliptinThe therapeutic efficacy of Evogliptin can be increased when used in combination with Ciprofloxacin.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ciprofloxacin.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ciprofloxacin.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Ciprofloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
FelodipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Ciprofloxacin.Approved
FenethyllineThe serum concentration of Fenethylline can be increased when it is combined with Ciprofloxacin.Approved
FenofibrateThe serum concentration of Ciprofloxacin can be increased when it is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Fenofibric acid.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved
FentanylThe serum concentration of Ciprofloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
Ferric ammonium citrateFerric ammonium citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseFerric Carboxymaltose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationFerric cation can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideFerric hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideFerric oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateFerric pyrophosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric pyrophosphate citrateFerric pyrophosphate citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric subsulfateFerric subsulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateFerric sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateFerrous bisglycinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideFerrous chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateFerrous fumarate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateFerrous gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateFerrous succinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateFerrous sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesFerumoxides can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilFerumoxsil can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolFerumoxytol can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of hyperkalemia can be increased when Fimasartan is combined with Ciprofloxacin.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Ciprofloxacin.Approved, Investigational
FirocoxibFirocoxib may increase the neuroexcitatory activities of Ciprofloxacin.Experimental, Vet Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Ciprofloxacin.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Withdrawn
FlucloroloneThe risk or severity of tendinopathy can be increased when Fluclorolone is combined with Ciprofloxacin.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ciprofloxacin.Approved, Investigational
FludrocortisoneThe risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Ciprofloxacin.Approved, Investigational
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Ciprofloxacin.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Ciprofloxacin.Withdrawn
FlumethasoneThe risk or severity of tendinopathy can be increased when Flumethasone is combined with Ciprofloxacin.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ciprofloxacin.Approved
FlunisolideThe risk or severity of tendinopathy can be increased when Flunisolide is combined with Ciprofloxacin.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ciprofloxacin.Approved, Illicit
FlunixinFlunixin may increase the neuroexcitatory activities of Ciprofloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of tendinopathy can be increased when Fluocinolone Acetonide is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of tendinopathy can be increased when Fluocinonide is combined with Ciprofloxacin.Approved, Investigational
FluocortinThe risk or severity of tendinopathy can be increased when Fluocortin is combined with Ciprofloxacin.Experimental
FluocortoloneThe risk or severity of tendinopathy can be increased when Fluocortolone is combined with Ciprofloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of tendinopathy can be increased when Fluorometholone is combined with Ciprofloxacin.Approved, Investigational
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Ciprofloxacin.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of tendinopathy can be increased when Fluperolone is combined with Ciprofloxacin.Experimental
FluphenazineThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of tendinopathy can be increased when Fluprednidene is combined with Ciprofloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of tendinopathy can be increased when Fluprednisolone is combined with Ciprofloxacin.Approved
FlurandrenolideThe risk or severity of tendinopathy can be increased when Flurandrenolide is combined with Ciprofloxacin.Approved
FlurazepamThe serum concentration of Ciprofloxacin can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Ciprofloxacin.Approved, Investigational
FluticasoneThe risk or severity of tendinopathy can be increased when Fluticasone is combined with Ciprofloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Ciprofloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Ciprofloxacin.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Ciprofloxacin.Approved, Investigational
ForasartanThe risk or severity of hyperkalemia can be increased when Forasartan is combined with Ciprofloxacin.Experimental
FormocortalThe risk or severity of tendinopathy can be increased when Formocortal is combined with Ciprofloxacin.Experimental
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Ciprofloxacin.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ciprofloxacin.Approved
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ciprofloxacin.Approved
FosinoprilatThe risk or severity of hyperkalemia can be increased when Fosinoprilat is combined with Ciprofloxacin.Experimental
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Ciprofloxacin.Approved, Investigational
FurafyllineThe serum concentration of Furafylline can be increased when it is combined with Ciprofloxacin.Experimental
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Ciprofloxacin.Approved
GallopamilThe serum concentration of Ciprofloxacin can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ciprofloxacin.Approved, Investigational
GefitinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gemifloxacin.Approved, Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be increased when used in combination with Ciprofloxacin.Investigational
GenisteinThe metabolism of Genistein can be decreased when combined with Ciprofloxacin.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Ciprofloxacin.Investigational
GlecaprevirThe serum concentration of Ciprofloxacin can be increased when it is combined with Glecaprevir.Approved, Investigational
GleptoferronGleptoferron can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be increased when used in combination with Ciprofloxacin.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be increased when used in combination with Ciprofloxacin.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Ciprofloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Ciprofloxacin.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be increased when used in combination with Ciprofloxacin.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Ciprofloxacin.Approved
GlycerinThe serum concentration of Ciprofloxacin can be increased when it is combined with Glycerin.Approved, Investigational
GlycodiazineThe therapeutic efficacy of Glycodiazine can be increased when used in combination with Ciprofloxacin.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be increased when used in combination with Ciprofloxacin.Investigational
Gramicidin DThe serum concentration of Ciprofloxacin can be increased when it is combined with Gramicidin D.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Ciprofloxacin.Approved, Investigational
GuanineThe serum concentration of Guanine can be increased when it is combined with Ciprofloxacin.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be increased when used in combination with Ciprofloxacin.Experimental
HalcinonideThe risk or severity of tendinopathy can be increased when Halcinonide is combined with Ciprofloxacin.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Halofantrine.Approved
HalometasoneThe risk or severity of tendinopathy can be increased when Halometasone is combined with Ciprofloxacin.Experimental
HaloperidolThe risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ciprofloxacin.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Ciprofloxacin.Approved
HM-30181The serum concentration of Ciprofloxacin can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Ciprofloxacin can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ciprofloxacin.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of tendinopathy can be increased when Hydrocortisone aceponate is combined with Ciprofloxacin.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Ciprofloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Ciprofloxacin.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of tendinopathy can be increased when Hydrocortisone probutate is combined with Ciprofloxacin.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of tendinopathy can be increased when Hydrocortisone succinate is combined with Ciprofloxacin.Approved
Hydrocortisone valerateThe risk or severity of tendinopathy can be increased when Hydrocortisone valerate is combined with Ciprofloxacin.Approved, Vet Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ciprofloxacin.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ciprofloxacin.Approved
HypoxanthineThe serum concentration of Hypoxanthine can be increased when it is combined with Ciprofloxacin.Experimental
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ciprofloxacin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ciprofloxacin.Approved
IbuprofenThe serum concentration of Ciprofloxacin can be increased when it is combined with Ibuprofen.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ibutilide.Approved
IcosapentIcosapent may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Nutraceutical
IdelalisibThe serum concentration of Ciprofloxacin can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Imatinib.Approved
ImidaprilThe risk or severity of hyperkalemia can be increased when Imidapril is combined with Ciprofloxacin.Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
ImipramineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Imipramine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ciprofloxacin.Approved, Investigational
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ciprofloxacin.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Ciprofloxacin.Approved
IndinavirThe serum concentration of Ciprofloxacin can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the neuroexcitatory activities of Ciprofloxacin.Investigational
IndomethacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be increased when used in combination with Ciprofloxacin.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be increased when used in combination with Ciprofloxacin.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be increased when used in combination with Ciprofloxacin.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be increased when used in combination with Ciprofloxacin.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Ciprofloxacin.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be increased when used in combination with Ciprofloxacin.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Ciprofloxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Ciprofloxacin.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be increased when used in combination with Ciprofloxacin.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be increased when used in combination with Ciprofloxacin.Approved
IrbesartanThe risk or severity of hyperkalemia can be increased when Irbesartan is combined with Ciprofloxacin.Approved, Investigational
IronIron can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranIron Dextran can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Iron isomaltoside 1000 can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateIron saccharate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Ciprofloxacin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ciprofloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Ciprofloxacin.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Ciprofloxacin.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Ciprofloxacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ivosidenib.Approved, Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Ciprofloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Ciprofloxacin.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Ciprofloxacin.Approved
KRP-104The therapeutic efficacy of KRP-104 can be increased when used in combination with Ciprofloxacin.Investigational
LaniquidarThe serum concentration of Ciprofloxacin can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateLanthanum carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Ciprofloxacin.Approved, Investigational
LedipasvirThe serum concentration of Ciprofloxacin can be increased when it is combined with Ledipasvir.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lenvatinib.Approved, Investigational
LetermovirThe serum concentration of Ciprofloxacin can be increased when it is combined with Letermovir.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Ciprofloxacin.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ciprofloxacin.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ciprofloxacin.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levomethadyl Acetate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ciprofloxacin.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ciprofloxacin.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be increased when used in combination with Ciprofloxacin.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Ciprofloxacin.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Ciprofloxacin.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be increased when used in combination with Ciprofloxacin.Approved
LisinoprilThe risk or severity of hyperkalemia can be increased when Lisinopril is combined with Ciprofloxacin.Approved, Investigational
LisofyllineThe serum concentration of Lisofylline can be increased when it is combined with Ciprofloxacin.Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lithium cation.Experimental
LixisenatideThe therapeutic efficacy of Lixisenatide can be increased when used in combination with Ciprofloxacin.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be increased when used in combination with Ciprofloxacin.Approved, Investigational
LobucavirThe serum concentration of Lobucavir can be increased when it is combined with Ciprofloxacin.Investigational
LofexidineThe metabolism of Lofexidine can be decreased when combined with Ciprofloxacin.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Ciprofloxacin can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Ciprofloxacin can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Ciprofloxacin can be increased when it is combined with Lonafarnib.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
LoperamideThe serum concentration of Ciprofloxacin can be increased when it is combined with Loperamide.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ciprofloxacin.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Ciprofloxacin.Approved
LoteprednolThe risk or severity of tendinopathy can be increased when Loteprednol is combined with Ciprofloxacin.Approved
LovastatinThe serum concentration of Ciprofloxacin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Ciprofloxacin can be increased when it is combined with Loxapine.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
LumacaftorThe serum concentration of Ciprofloxacin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Macimorelin.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ciprofloxacin.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be increased when used in combination with Ciprofloxacin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of tendinopathy can be increased when Medrysone is combined with Ciprofloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Ciprofloxacin.Approved, Investigational
Megestrol acetateThe serum concentration of Ciprofloxacin can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Ciprofloxacin.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of tendinopathy can be increased when Melengestrol is combined with Ciprofloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ciprofloxacin.Investigational, Withdrawn
MeprednisoneThe risk or severity of tendinopathy can be increased when Meprednisone is combined with Ciprofloxacin.Approved, Investigational
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ciprofloxacin.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Ciprofloxacin.Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mesoridazine.Approved, Investigational
MetahexamideThe therapeutic efficacy of Metahexamide can be increased when used in combination with Ciprofloxacin.Experimental
MetamizoleMetamizole may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.Approved
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Ciprofloxacin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.Approved
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ciprofloxacin.Approved, Investigational
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Ciprofloxacin.Approved, Vet Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ciprofloxacin.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Ciprofloxacin.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Mevastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Ciprofloxacin.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Ciprofloxacin.Approved, Investigational
MibefradilThe serum concentration of Ciprofloxacin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ciprofloxacin can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be increased when used in combination with Ciprofloxacin.Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ciprofloxacin.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Ciprofloxacin.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
MitotaneThe serum concentration of Ciprofloxacin can be increased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ciprofloxacin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MocetinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mocetinostat.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
MometasoneThe risk or severity of tendinopathy can be increased when Mometasone is combined with Ciprofloxacin.Approved, Vet Approved
Mometasone furoateThe risk or severity of tendinopathy can be increased when Mometasone furoate is combined with Ciprofloxacin.Approved, Vet Approved
MonensinThe serum concentration of Ciprofloxacin can be increased when it is combined with Monensin.Vet Approved
MorniflumateMorniflumate may increase the neuroexcitatory activities of Ciprofloxacin.Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ciprofloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.Approved
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Ciprofloxacin.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Nalidixic Acid.Approved, Investigational
NaproxenThe metabolism of Naproxen can be decreased when combined with Ciprofloxacin.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be increased when used in combination with Ciprofloxacin.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ciprofloxacin.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Nemonoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
NeratinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be increased when used in combination with Ciprofloxacin.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ciprofloxacin.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Ciprofloxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved
NigericinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Ciprofloxacin.Investigational
NitroprussideNitroprusside can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NN344The therapeutic efficacy of NN344 can be increased when used in combination with Ciprofloxacin.Investigational
NordazepamThe metabolism of Nordazepam can be decreased when combined with Ciprofloxacin.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ciprofloxacin.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ciprofloxacin.Approved
NS-398NS-398 may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ciprofloxacin.Approved, Investigational
OlmesartanThe risk or severity of hyperkalemia can be increased when Olmesartan is combined with Ciprofloxacin.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ciprofloxacin.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Ciprofloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved
OmapatrilatThe risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Ciprofloxacin.Investigational
OmarigliptinThe therapeutic efficacy of Omarigliptin can be increased when used in combination with Ciprofloxacin.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ondansetron.Approved
ONT-093The serum concentration of Ciprofloxacin can be increased when it is combined with ONT-093.Investigational
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Ciprofloxacin.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Ciprofloxacin.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Oxaliplatin.Approved, Investigational
OxaprozinOxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Ciprofloxacin.Experimental
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Ciprofloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.Approved, Vet Approved
PaclitaxelThe serum concentration of Ciprofloxacin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Ciprofloxacin can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Papaverine.Approved, Investigational
ParamethasoneThe risk or severity of tendinopathy can be increased when Paramethasone is combined with Ciprofloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved
ParitaprevirThe serum concentration of Ciprofloxacin can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Ciprofloxacin.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ciprofloxacin.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Ciprofloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ciprofloxacin.Approved
PeldesineThe serum concentration of Peldesine can be increased when it is combined with Ciprofloxacin.Experimental, Investigational
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Ciprofloxacin.Approved, Investigational
PenciclovirThe serum concentration of Penciclovir can be increased when it is combined with Ciprofloxacin.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Ciprofloxacin.Approved, Investigational
PentazocineThe serum concentration of Ciprofloxacin can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentifyllineThe serum concentration of Pentifylline can be increased when it is combined with Ciprofloxacin.Experimental
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Ciprofloxacin.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Ciprofloxacin.Approved
PerflubutanePerflubutane can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Perflutren.Approved
PerindoprilThe risk or severity of hyperkalemia can be increased when Perindopril is combined with Ciprofloxacin.Approved
PerindoprilatThe risk or severity of hyperkalemia can be increased when Perindoprilat is combined with Ciprofloxacin.Experimental
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ciprofloxacin.Approved
PethidineThe serum concentration of Ciprofloxacin can be increased when it is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ciprofloxacin.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be increased when used in combination with Ciprofloxacin.Approved, Investigational, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be increased when used in combination with Ciprofloxacin.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ciprofloxacin.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Ciprofloxacin.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Vet Approved
PhenytoinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Ciprofloxacin.Approved, Vet Approved
PibrentasvirThe serum concentration of Ciprofloxacin can be increased when it is combined with Pibrentasvir.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ciprofloxacin.Approved
PimobendanThe metabolism of Pimobendan can be decreased when combined with Ciprofloxacin.Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be increased when used in combination with Ciprofloxacin.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Ciprofloxacin.Experimental
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Ciprofloxacin.Experimental
PiroxicamPiroxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Pitavastatin.Approved
PitolisantThe serum concentration of Ciprofloxacin can be decreased when it is combined with Pitolisant.Approved, Investigational
PolaprezincPolaprezinc can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.Approved
PonatinibThe serum concentration of Ciprofloxacin can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pracinostat.Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Experimental, Investigational
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Pravastatin.Approved
PrazosinThe serum concentration of Ciprofloxacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of tendinopathy can be increased when Prednicarbate is combined with Ciprofloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Ciprofloxacin.Approved, Vet Approved
PrednisoneThe serum concentration of Ciprofloxacin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednylideneThe risk or severity of tendinopathy can be increased when Prednylidene is combined with Ciprofloxacin.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Primaquine.Approved
ProbenecidProbenecid may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.Approved, Investigational
ProbucolThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Procainamide.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ciprofloxacin.Approved, Vet Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Ciprofloxacin.Approved
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Ciprofloxacin.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Ciprofloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Propafenone.Approved
PropentofyllineThe serum concentration of Propentofylline can be increased when it is combined with Ciprofloxacin.Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Ciprofloxacin.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Ciprofloxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ciprofloxacin.Approved
ProxyphyllineThe serum concentration of Proxyphylline can be increased when it is combined with Ciprofloxacin.Experimental
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Ciprofloxacin.Investigational
Prussian bluePrussian blue can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuercetinThe serum concentration of Ciprofloxacin can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Ciprofloxacin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilQuinapril can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatThe risk or severity of hyperkalemia can be increased when Quinaprilat is combined with Ciprofloxacin.Experimental
QuinidineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quinine.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ciprofloxacin.Approved, Investigational
RamiprilThe risk or severity of hyperkalemia can be increased when Ramipril is combined with Ciprofloxacin.Approved
RamiprilatThe risk or severity of hyperkalemia can be increased when Ramiprilat is combined with Ciprofloxacin.Experimental
RamosetronThe metabolism of Ramosetron can be decreased when combined with Ciprofloxacin.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ciprofloxacin.Approved
RanolazineThe serum concentration of Ciprofloxacin can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Ciprofloxacin.Approved
ReboxetineThe serum concentration of Ciprofloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ciprofloxacin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
RescinnamineThe risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Ciprofloxacin.Approved
ReserpineThe serum concentration of Ciprofloxacin can be increased when it is combined with Reserpine.Approved, Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Ciprofloxacin.Approved, Experimental, Investigational
Reversin 121The serum concentration of Ciprofloxacin can be increased when it is combined with Reversin 121.Experimental
RibociclibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ricolinostat.Investigational
RifampicinThe serum concentration of Ciprofloxacin can be increased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ciprofloxacin.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Ciprofloxacin.Approved, Investigational
RimexoloneThe risk or severity of tendinopathy can be increased when Rimexolone is combined with Ciprofloxacin.Approved
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Ciprofloxacin.Approved, Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ciprofloxacin.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be increased when used in combination with Ciprofloxacin.Experimental, Investigational
RobenacoxibRobenacoxib may increase the neuroexcitatory activities of Ciprofloxacin.Experimental, Vet Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be increased when it is combined with Ciprofloxacin.Approved
RolapitantThe serum concentration of Ciprofloxacin can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Romidepsin.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ronifibrate.Experimental
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Ciprofloxacin.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Ciprofloxacin.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ciprofloxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Ciprofloxacin.Approved, Investigational
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Ciprofloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Ciprofloxacin.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ciprofloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Ciprofloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Ciprofloxacin can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ciprofloxacin.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Ciprofloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Ciprofloxacin.Approved
SaprisartanThe risk or severity of hyperkalemia can be increased when Saprisartan is combined with Ciprofloxacin.Experimental
SaquinavirThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Ciprofloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of hyperkalemia can be increased when Saralasin is combined with Ciprofloxacin.Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Ciprofloxacin.Approved
SC-236SC-236 may increase the neuroexcitatory activities of Ciprofloxacin.Experimental, Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Ciprofloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Ciprofloxacin.Approved, Vet Approved
SimeprevirThe serum concentration of Ciprofloxacin can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ciprofloxacin is combined with Simvastatin.Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Ciprofloxacin.Approved, Investigational
Sodium feredetateSodium feredetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium ferric gluconate complexSodium ferric gluconate complex can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Ciprofloxacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ciprofloxacin.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with Ciprofloxacin.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of hyperkalemia can be increased when Spirapril is combined with Ciprofloxacin.Approved
SpironolactoneSpironolactone may increase the arrhythmogenic activities of Ciprofloxacin.Approved
StaurosporineThe serum concentration of Ciprofloxacin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe metabolism of Stiripentol can be decreased when combined with Ciprofloxacin.Approved
Strontium ranelateStrontium ranelate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
SucralfateSucralfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be increased when used in combination with Ciprofloxacin.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Ciprofloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Ciprofloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sultopride.Experimental
SunitinibThe therapeutic efficacy of Sunitinib can be increased when used in combination with Ciprofloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Withdrawn
SuvorexantThe serum concentration of Ciprofloxacin can be increased when it is combined with Suvorexant.Approved, Investigational
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
TacrineThe metabolism of Tacrine can be decreased when combined with Ciprofloxacin.Investigational, Withdrawn
TacrolimusThe serum concentration of Ciprofloxacin can be increased when it is combined with Tacrolimus.Approved, Investigational
TalniflumateTalniflumate may increase the neuroexcitatory activities of Ciprofloxacin.Approved
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ciprofloxacin.Approved
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ciprofloxacin.Investigational
TariquidarThe serum concentration of Ciprofloxacin can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Ciprofloxacin.Approved, Investigational
TasosartanThe risk or severity of hyperkalemia can be increased when Tasosartan is combined with Ciprofloxacin.Approved
TaspoglutideThe therapeutic efficacy of Taspoglutide can be increased when used in combination with Ciprofloxacin.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Technetium Tc-99m ciprofloxacin.Investigational
TegafurThe metabolism of Tegafur can be decreased when combined with Ciprofloxacin.Approved, Investigational
TelaprevirThe serum concentration of Ciprofloxacin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Telithromycin.Approved
TelmisartanThe risk or severity of hyperkalemia can be increased when Telmisartan is combined with Ciprofloxacin.Approved, Investigational
TemafloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of hyperkalemia can be increased when Temocapril is combined with Ciprofloxacin.Experimental, Investigational
TemsirolimusThe serum concentration of Ciprofloxacin can be increased when it is combined with Temsirolimus.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Ciprofloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Ciprofloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Ciprofloxacin.Vet Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ciprofloxacin.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ciprofloxacin.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terodiline.Experimental
TesmilifeneThe serum concentration of Ciprofloxacin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Tetrabenazine.Approved, Investigational
Tetraferric tricitrate decahydrateTetraferric tricitrate decahydrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrandrineThe serum concentration of Ciprofloxacin can be increased when it is combined with Tetrandrine.Experimental
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
TheodrenalineThe serum concentration of Theodrenaline can be increased when it is combined with Ciprofloxacin.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ciprofloxacin.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ciprofloxacin.Approved
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Ciprofloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved
TicagrelorThe serum concentration of Ciprofloxacin can be increased when it is combined with Ticagrelor.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Ciprofloxacin.Investigational
TioclomarolThe therapeutic efficacy of Tioclomarol can be increased when used in combination with Ciprofloxacin.Experimental
TipifarnibThe serum concentration of Ciprofloxacin can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Ciprofloxacin can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of tendinopathy can be increased when Tixocortol is combined with Ciprofloxacin.Approved, Withdrawn
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Ciprofloxacin.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Ciprofloxacin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ciprofloxacin.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of hyperkalemia can be increased when Trandolapril is combined with Ciprofloxacin.Approved
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Ciprofloxacin.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ciprofloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of tendinopathy can be increased when Triamcinolone is combined with Ciprofloxacin.Approved, Vet Approved
TriamtereneThe metabolism of Triamterene can be decreased when combined with Ciprofloxacin.Approved
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Ciprofloxacin.Approved, Investigational
TriflupromazineThe serum concentration of Ciprofloxacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrilostaneThe risk or severity of tendinopathy can be increased when Trilostane is combined with Ciprofloxacin.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Ciprofloxacin.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Ciprofloxacin.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ciprofloxacin.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ciprofloxacin.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be increased when used in combination with Ciprofloxacin.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Ciprofloxacin.Approved
TroleandomycinThe serum concentration of Ciprofloxacin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Tucidinostat.Investigational
UlobetasolThe risk or severity of tendinopathy can be increased when Ulobetasol is combined with Ciprofloxacin.Approved
Uric AcidThe serum concentration of Uric Acid can be increased when it is combined with Ciprofloxacin.Experimental, Investigational
VadimezanThe metabolism of Vadimezan can be decreased when combined with Ciprofloxacin.Investigational
ValaciclovirThe serum concentration of Valaciclovir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ValinomycinThe serum concentration of Ciprofloxacin can be increased when it is combined with Valinomycin.Experimental
ValomaciclovirThe serum concentration of Valomaciclovir can be increased when it is combined with Ciprofloxacin.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of hyperkalemia can be increased when Valsartan is combined with Ciprofloxacin.Approved, Investigational
ValspodarThe serum concentration of Ciprofloxacin can be increased when it is combined with Valspodar.Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Ciprofloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Ciprofloxacin.Approved, Investigational
VelpatasvirThe serum concentration of Ciprofloxacin can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Ciprofloxacin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ciprofloxacin.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Ciprofloxacin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Ciprofloxacin.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be increased when used in combination with Ciprofloxacin.Approved, Investigational
VinblastineThe serum concentration of Ciprofloxacin can be increased when it is combined with Vinblastine.Approved
VoacamineThe serum concentration of Ciprofloxacin can be increased when it is combined with Voacamine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be increased when used in combination with Ciprofloxacin.Approved, Investigational
VorapaxarThe serum concentration of Ciprofloxacin can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ciprofloxacin.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ciprofloxacin.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Ciprofloxacin.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Ciprofloxacin.Approved
XanthineThe serum concentration of Xanthine can be increased when it is combined with Ciprofloxacin.Experimental
YohimbineThe serum concentration of Ciprofloxacin can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
ZileutonThe metabolism of Zileuton can be decreased when combined with Ciprofloxacin.Approved, Investigational, Withdrawn
ZincZinc can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc acetateZinc acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc ascorbateZinc ascorbate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Zinc carbonateZinc carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc cationZinc cation can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc chlorideZinc chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc citrateZinc citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc DibutyldithiocarbamateZinc Dibutyldithiocarbamate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc gluconateZinc gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Zinc glycinateZinc glycinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc oxideZinc oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc picolinateZinc picolinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc Substituted Heme CZinc Substituted Heme C can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc sulfateZinc sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc sulfate, unspecified formZinc sulfate, unspecified form can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Zinc TrihydroxideZinc Trihydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of hyperkalemia can be increased when Zofenopril is combined with Ciprofloxacin.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Ciprofloxacin.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ciprofloxacin.Approved
ZomepiracThe serum concentration of Ciprofloxacin can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Ciprofloxacin can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe metabolism of Zotepine can be decreased when combined with Ciprofloxacin.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, magnesium, zinc, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water.
  • Take without regard to meals.

References

Synthesis Reference
US4670444
General References
  1. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J: Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. [PubMed:3777908]
  2. Hilliard JJ, Krause HM, Bernstein JI, Fernandez JA, Nguyen V, Ohemeng KA, Barrett JF: A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol. 1995;390:59-69. [PubMed:8718602]
  3. Spivey JM, Cummings DM, Pierson NR: Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy. 1996 Mar-Apr;16(2):314-6. [PubMed:8820479]
  4. Brouwers JR: Drug interactions with quinolone antibacterials. Drug Saf. 1992 Jul-Aug;7(4):268-81. [PubMed:1524699]
External Links
Human Metabolome Database
HMDB0014677
KEGG Drug
D00186
KEGG Compound
C05349
PubChem Compound
2764
PubChem Substance
46504733
ChemSpider
2662
BindingDB
21690
ChEBI
100241
ChEMBL
CHEMBL8
Therapeutic Targets Database
DAP001360
PharmGKB
PA449009
HET
CPF
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ciprofloxacin
ATC Codes
J01MA02 — CiprofloxacinJ01RA11 — Ciprofloxacin and tinidazoleJ01RA12 — Ciprofloxacin and ornidazoleS02AA15 — CiprofloxacinS01AE03 — CiprofloxacinS03AA07 — CiprofloxacinJ01RA10 — Ciprofloxacin and metronidazole
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.18 — Quinolones
PDB Entries
1oye / 1t9u / 2xct / 4bvv / 4kra / 5btc
FDA label
Download (120 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAlcoholic Cirrhosis / Alcoholic Hepatitis (AH)1
0Enrolling by InvitationBasic ScienceDietary Modifications / Nutrition1
0Not Yet RecruitingTreatmentRhinoscleroma1
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableBacterial Infections / Brain Injury1
1CompletedNot AvailableDysbacteriosis1
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailableMetabolic Detoxication, Phase I1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedOtherHealthy Volunteers / Non-Smokers1
1CompletedPreventionEscherichia Coli Infections1
1CompletedTreatmentBacillus Anthracis (Anthrax)1
1CompletedTreatmentBilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement1
1CompletedTreatmentCystic Fibrosis (CF)2
1CompletedTreatmentHealthy Volunteers / Purpura, Thrombocytopaenic, Idiopathic / Purpura, Thrombocytopenic, Idiopathic1
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentInfection NOS / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentPseudomonas Infections1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive2
1CompletedTreatmentPulmonary Diseases1
1CompletedTreatmentRespiratory System1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentConjunctivitis / Conjunctivitis, Bacterial1
1SuspendedTreatmentAnthrax1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentEar Diseases / Otitis / Otitis Externa / Otorhinolaryngologic Diseases1
1, 2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemias1
1, 2TerminatedTreatmentDiabetic Foot Ulcers (DFU)1
1, 2Unknown StatusPreventionHard of Hearing1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedPreventionCrohn's Disease (CD)1
2CompletedPreventionCystic Fibrosis (CF) / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentAcute Otitis Media / AOMT1
2CompletedTreatmentAcute Bacterial Corneal Ulcers / Bacterial Keratitis1
2CompletedTreatmentAnthrax1
2CompletedTreatmentBronchiectasis1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCritical Illness / Hospital Acquired Infections / Pneumonia / Pyrexia / Systemic Inflammatory Response Syndrome (SIRS)1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentEar Diseases / Otitis / Otitis Externa / Otorhinolaryngologic Diseases2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
2CompletedTreatmentNon-Cystic Fibrosis Bronchiectasis1
2CompletedTreatmentOtitis Externa1
2CompletedTreatmentPyelonephritis / Urinary Tract Infections (UTIs)1
2CompletedTreatmentUrinary Tract Infections (UTIs)1
2Not Yet RecruitingPreventionLeak, Anastomotic / Rectal Carcinoma1
2Not Yet RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingPreventionProstate Infections1
2RecruitingTreatmentAdherent-invasive E. Coli / Crohn's Disease (CD)1
2RecruitingTreatmentCrohn's Disease (CD)2
2RecruitingTreatmentInfected Immature Permanent Teeth1
2TerminatedTreatmentAcute Otitis Media1
2TerminatedTreatmentCrohn's Disease (CD)1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2TerminatedTreatmentOsteomyelitis1
2Unknown StatusTreatmentPlague1
2WithdrawnDiagnosticProstate Cancer1
3Active Not RecruitingTreatmentBenign Lymphoepithelial Lesion / Human Immunodeficiency Virus (HIV) / Salivary Gland Diseases1
3Active Not RecruitingTreatmentTravelers' Diarrhea1
3CompletedNot AvailableAcute Otitis Media1
3CompletedPreventionBacterial Infections1
3CompletedSupportive CareInfection NOS / Multiple Myeloma (MM)1
3CompletedTreatmentAcute Otitis Externa1
3CompletedTreatmentAcute Otitis Externa / Swimmer's Ear1
3CompletedTreatmentAntibiotics / Chronic Obstructive Pulmonary Disease (COPD) / Sepsis1
3CompletedTreatmentBacterial Infections / Minor burns1
3CompletedTreatmentBronchiectasis1
3CompletedTreatmentCancer, Breast / Cyclophosphamide / Doxorubicin / High Risk / Positive Nodes1
3CompletedTreatmentCholera2
3CompletedTreatmentCrohn's Disease With Perianal Fistulas1
3CompletedTreatmentInfectious Diseases1
3CompletedTreatmentNeutropenia, Febrile1
3CompletedTreatmentOtitis Externa1
3CompletedTreatmentOtitis Media (OM)1
3CompletedTreatmentPneumonia1
3CompletedTreatmentUrinary Tract Infections (UTIs)2
3Not Yet RecruitingTreatmentAntibiotic Resistant Infection / Complicated skin infection bacterial / Complicated Urinary Tract Infections / Urinary Tract Infections (UTIs)1
3Not Yet RecruitingTreatmentAntibiotic Resistant Infection / Complicated skin infection bacterial / Intra Abdominal Infections1
3Not Yet RecruitingTreatmentAntibiotic Resistant Infection / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs)1
3Not Yet RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3RecruitingTreatmentEnterobacteriaceae Infections1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
3TerminatedPreventionMen Who Must Undergo a Prostate Biopsy Related to Prostate Cancer Suspicion1
3TerminatedPreventionUrolithiasis1
3TerminatedTreatmentAcute Otitis Externa1
3TerminatedTreatmentBladder Cancers1
3TerminatedTreatmentCancers / Fevers / Neutropenias1
3TerminatedTreatmentDiverticular Sigmoïditis1
3TerminatedTreatmentElevated Prostate Specific Antigen1
3TerminatedTreatmentOtitis Externa1
3TerminatedTreatmentOtitis Media in Patients With Tympanostomy Tubes1
3Unknown StatusSupportive CareBrain and Central Nervous System Tumors / Malignant Lymphomas / Neutropenias / Psychosocial Effects of Cancer and Its Treatment / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentAcute Otitis Externa1
3WithdrawnPreventionSpontaneous Bacterial Peritonitis (SBP)1
4Active Not RecruitingTreatmentInfection NOS1
4CompletedNot AvailablePregnancy1
4CompletedPreventionAdverse Reaction to Other Drugs and Medicines1
4CompletedPreventionBacteriuria / Urinary Tract Infections (UTIs)1
4CompletedPreventionBenign Prostatic Hyperplasia (BPH)1
4CompletedPreventionMeningococcal Meningitis1
4CompletedPreventionUrinary Tract Infections (UTIs)1
4CompletedSupportive CareCancer, Breast1
4CompletedTreatmentCataracts1
4CompletedTreatmentChlamydia Trachomatis / Human Immunodeficiency Virus (HIV) / Neisseria Gonorrhoeae Infection1
4CompletedTreatmentFevers / Urinary Tract Infections (UTIs)1
4CompletedTreatmentLiver Cirrhosis / SBP1
4CompletedTreatmentPeriodontitis, Chronic1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPyelonephritis / Urinary Tract Infections (UTIs)1
4CompletedTreatmentUlcerative Colitis (UC)1
4CompletedTreatmentUncomplicated Bacterial Cystitis1
4CompletedTreatmentUrinary Tract Infections (UTIs)4
4Enrolling by InvitationTreatmentSmall Intestinal Bacterial Overgrowth1
4Not Yet RecruitingPreventionMeningococcal Meningitis1
4Not Yet RecruitingTreatmentOtitis Media (OM) / Otorrhoea1
4Not Yet RecruitingTreatmentOtitis Media With Effusion in Children / Otorrhoea1
4RecruitingOtherChronic Obstructive Pulmonary Disease (COPD) / Pseudomonas Aeruginosa / Respiratory Tract Infections (RTI)1
4RecruitingPreventionBK Virus Infection1
4RecruitingPreventionRenal Stones1
4RecruitingSupportive CarePancreatic Cystic Lesions1
4RecruitingTreatmentAntibiotic Resistant Infection / UTI - Lower Urinary Tract Infection1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentCritical Illness / Mechanical Ventilation Complication1
4RecruitingTreatmentEarly Stage Breast Cancer1
4RecruitingTreatmentUlcerative Colitis (UC)1
4SuspendedTreatmentGallstone formation1
4TerminatedDiagnosticProstate Infections1
4WithdrawnDiagnosticAscites / Infection NOS / Liver Cirrhosis1
Not AvailableActive Not RecruitingPreventionCatheter-Related Infections / Urinary Tract Infections (UTIs)1
Not AvailableActive Not RecruitingSupportive CareAscites (Non-Malignant) / Ascites Hepatic / Liver Cirrhosis1
Not AvailableCompletedNot AvailableAcute Cystitis1
Not AvailableCompletedNot AvailableBronchiectasis / Pulmonary Disease, Chronic Obstructive1
Not AvailableCompletedNot AvailableInfection NOS2
Not AvailableCompletedBasic ScienceEndotoxaemia1
Not AvailableCompletedBasic ScienceHealthy Volunteers / Sepsis1
Not AvailableCompletedPreventionPancreatic Cysts1
Not AvailableCompletedScreeningBacterial Resistance1
Not AvailableCompletedTreatmentAppendicitis / Children1
Not AvailableCompletedTreatmentCeftazidime / Ciprofloxacin / Pediatrics / Voriconazole1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableCompletedTreatmentUrinary Tract Infections (UTIs)1
Not AvailableNot Yet RecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableCystitis / Pyelonephritis / Cystic Fibrosis / Anthrax1
Not AvailableRecruitingDiagnosticGonorrhoea1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingPreventionUrolithiasis / UTI1
Not AvailableRecruitingTreatmentBronchiectasis1
Not AvailableRecruitingTreatmentLiver Abscess, Pyogenic1
Not AvailableTerminatedSupportive CareChronic Myeloproliferative Disorders / Fever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neutropenias / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentClostridium Difficile / Prostate Cancer / Urinary Tract Infections (UTIs)1
Not AvailableTerminatedTreatmentHealthy Volunteers1
Not AvailableUnknown StatusTreatmentDiabetic Foot / Diabetic Foot Ulcers (DFU) / Osteomyelitis1
Not AvailableUnknown StatusTreatmentPeritonitis1

Pharmacoeconomics

Manufacturers
  • Bayer healthcare pharmaceuticals inc
  • Bayer pharmaceuticals corp
  • App pharmaceuticals llc
  • Bedford laboratories
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • West ward pharmaceutical corp
  • Hikma farmaceutica (portugal) sa
  • Acs dobfar info sa
  • Baxter healthcare corp
  • Bedford laboratories div ben venue laboratories inc
  • Alcon inc
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • Fdc ltd
  • Hitech pharmacal corp
  • Nexus pharmaceuticals inc
  • Novex pharma
  • Pharmaforce inc
  • Wraser pharmaceuticals llc
  • Depomed inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Hikma pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Pliva inc
  • Ranbaxy pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Unique pharmaceutical laboratories
  • Watson laboratories inc
  • Allergan inc
Packagers
  • ACS Dobfar SPA
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Amerisource Health Services Corp.
  • Anchen Pharmaceuticals Inc.
  • Apotex Inc.
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • Arrow Pharm Malta Ltd.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Bausch & Lomb Inc.
  • Baxter International Inc.
  • Bayer Healthcare
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Blenheim Pharmacal
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlsbad Technology Inc.
  • Claris Lifesciences Inc.
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Core Pharmaceuticals
  • Daiichi Sankyo
  • Depomed Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Dorx LLC
  • Esprit Pharma Inc.
  • Falcon Pharmaceuticals Ltd.
  • Forum Products Inc.
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • H.J. Harkins Co. Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Hikma Pharmaceuticals
  • Hospira Inc.
  • Indoco Remedies Limited
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • J.B. Chemicals & Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Kenyon Drug Co.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Matrix Laboratories Ltd.
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nexus Pharmaceuticals
  • Northstar Rx LLC
  • Novartis AG
  • Novex Pharma
  • Nucare Pharmaceuticals Inc.
  • Pack Pharmaceuticals
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmaforce Inc.
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prescription Dispensing Service Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sagent Pharmaceuticals
  • Sandhills Packaging Inc.
  • Sandoz
  • Schering Corp.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stat Scripts LLC
  • Taro Pharmaceuticals USA
  • Testpak Holding Company Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • West-Ward Pharmaceuticals
  • WraSer Pharmaceuticals
  • Yung Shin Pharmaceutical Industry Ltd.
Dosage forms
FormRouteStrength
OintmentOphthalmic0.3 %
OintmentOphthalmic3 mg/g
SolutionOphthalmic3.5 mg/mL
Kit
Solution, concentrateIntravenous2 mg/mL
SuspensionAuricular (otic)
LiquidIntravenous10 mg
SuspensionOral500 mg
TabletOral100 mg
Tablet, extended releaseOral1000 mg
Tablet, extended releaseOral500 mg
Suspension / dropsAuricular (otic)
InjectionIntravenous10 mg/mL
InjectionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
Injection, solution, concentrateIntravenous10 mg/mL
Injection, solution, concentrateIntravenous200 mg/20mL
Injection, solution, concentrateIntravenous400 mg/40mL
Solution / dropsOphthalmic3 mg/mL
Solution / dropsOphthalmic3.5 mg/mL
Solution / dropsOphthalmic; Topical3 mg/mL
Solution / dropsTopical3 mg/mL
Solution / dropsTopical3.5 mg/1
Solution / dropsTopical3.5 mg/mL
TabletOral250 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, coatedOral500 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
Tablet, film coated, extended releaseOral
SolutionOphthalmic3 mg/mL
SolutionIntravenous0.2 %
SolutionIntravenous10 mg
SolutionIntravenous2.0 mg
SolutionIntravenous2 mg
Solution / dropsAuricular (otic).5 mg/.25mL
SuspensionIntratympanic6 mg/mL
SolutionAuricular (otic)
For solutionAuricular (otic)
Tablet, film coated, extended releaseOral500 mg/1
SolutionOphthalmic0.3 %
TabletOral250 mg
TabletOral500 mg
TabletOral750 mg
Prices
Unit descriptionCostUnit
Cipro 400 mg Solution 40ml Vial259.99USD vial
Floxin Otic 0.3% Solution 10ml Bottle142.91USD bottle
Cipro 500 mg/5ml(10%) Suspension 100ml Bottle136.75USD bottle
Cipro HC 0.2-1% Suspension 10ml Bottle131.54USD bottle
Cipro 250 mg/5ml(5%) Suspension 100ml Bottle116.8USD bottle
Ocuflox 0.3% Solution 10ml Bottle106.09USD bottle
Ciprofloxacin HCl 0.3% Solution 10ml Bottle98.22USD bottle
Ciloxan 0.3% Ointment 3.5 gm Tube87.49USD tube
Floxin Otic 0.3% Solution 5ml Bottle86.49USD bottle
Ciloxan 0.3% Solution 5ml Bottle68.33USD bottle
Ocuflox 0.3% Solution 5ml Bottle57.32USD bottle
Ciprofloxacin HCl 0.3% Solution 5ml Bottle49.2USD bottle
ProQuin XR 3 500 mg 24 Hour tablet Disp Pack39.99USD disp
Ciprofloxacin HCl 0.3% Solution 2.5ml Bottle26.03USD bottle
Ciloxan 0.3% eye drops13.33USD ml
Ciprofloxacin 0.3% eye drop12.96USD ml
Cipro hc otic suspension12.65USD ml
Proquin xr 500 mg tablet12.18USD tablet
Cipro xr 1000 mg tablet11.91USD tablet
Ciprofloxacin-Ciproflox HCl 1000 mg 24 Hour tablet11.6USD tablet
Ocuflox 0.3% eye drops11.35USD ml
ProQuin XR 500 mg 24 Hour tablet11.18USD tablet
Ciprofloxacin er 1000 mg tablet11.16USD tablet
Cipro XR 500 mg 24 Hour tablet10.88USD tablet
Cipro XR 1000 mg 24 Hour tablet10.75USD tablet
Cipro xr 500 mg tablet10.46USD tablet
Ciprofloxacin-Ciproflox HCl 500 mg 24 Hour tablet10.19USD tablet
Ciprofloxacin er 500 mg tablet9.8USD tablet
Floxin 400 mg tablet9.55USD tablet
Cetraxal 0.2% ear solution7.14USD each
Floxin 200 mg tablet6.6USD tablet
Cipro 750 mg tablet6.26USD tablet
Cipro 500 mg tablet6.08USD tablet
Ciprofloxacin hcl 750 mg tablet5.65USD tablet
Floxin 300 mg tablet5.61USD tablet
Ciprofloxacin hcl 500 mg tablet5.59USD tablet
Cipro 250 mg tablet5.2USD tablet
Ciprofloxacin hcl 250 mg tablet4.59USD tablet
Floxin otic singles4.28USD each
Ciprofloxacin hcl 100 mg tablet4.17USD tablet
Ciloxan 0.3 % Solution2.18USD ml
Ciprofloxacin hcl powder1.29USD g
Apo-Ciproflox 0.3 % Solution1.18USD ml
Pms-Ciprofloxacin 0.3 % Solution1.18USD ml
Cipro i.v. 10 mg/ml vial0.72USD ml
Cipro i.v. 200 mg/100 ml d5w0.16USD ml
Ciprofloxacin 200 mg/20 ml vial0.13USD ml
Ciprofloxacn-d5w 200 mg/100 ml0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5286754No1994-02-152011-02-15Us
CA2414271No2005-09-272021-06-13Canada
CA1330946No1994-07-262011-07-26Canada
US8187632Yes2001-12-232021-12-23Us
US7709022Yes2001-12-232021-12-23Us
US8846650No2005-06-042025-06-04Us
US9149486No2002-09-132022-09-13Us
US6359016No2000-08-102020-08-10Us
US6284804No2000-08-102020-08-10Us
US5972389No1996-09-192016-09-19Us
US6340475No1996-09-192016-09-19Us
US6635280No1996-09-192016-09-19Us
US6488962No2000-06-202020-06-20Us
US9205048No2009-04-212029-04-21Us
US8318817No2010-04-272030-04-27Us
US9220796No2015-07-012035-07-01Us
US9233068No2009-12-112029-12-11Us
US8932610No2010-03-242030-03-24Us
US9345714No2002-09-132022-09-13Us
US9402805No2002-09-132022-09-13Us
US9603796No2009-04-212029-04-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)255-257 °CNot Available
water solubility3E+004 mg/L (at 20 °C)NOWARA,A ET AL. (1997)
logP0.28TAKACS-NOVAK,K ET AL. (1992)
pKa6.09TORNIANEN,K ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility1.35 mg/mLALOGPS
logP-0.57ALOGPS
logP-0.81ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.76ChemAxon
pKa (Strongest Basic)8.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity87.94 m3·mol-1ChemAxon
Polarizability33.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0029000000-1366c290ed86c001f05b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dr-0069000000-a523751ea781088af897
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0009000000-f29d9954b2b055b62079
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01qi-0039000000-9cb66ef0790c686ea2b2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0089000000-c501b014ce11307842e1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0092000000-3f2bc2af8897693f406a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0290000000-97cd08c23e39dd2412ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0690000000-c683e1591a42526bd85d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0009000000-c8783567d83c0158dc21
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01qi-0049000000-0c3e1fd26ebdc13a760e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0079000000-84eeb4205e8a902133ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0192000000-3bebeb08e817739aa5f7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0290000000-40a5de8dd981d46dbe88
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0690000000-827770181ddec7977048
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dr-0079000000-b9937740f37fc8a939a6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0009000000-06b6d10cecb7c9cab240
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0129000000-61453c8af95773ec6b29
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03dr-0296000000-de128c8d0e1eade700b6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0gx1-1292000000-2d8ff05ee839372800db
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-1290000000-f3446636040c80d0f8a3
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0090000000-6fc954ec7c93eaabef55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001j-0198000000-0bfdea918825b34619d5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-5cee2f47095630088ff6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01p9-0095000000-c780444ec059d2f2f98e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01p9-0095000000-1dc83645e6c6c47ab02f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0920000000-9769fb468772887a192f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0397000000-0e08dc88a42e413750ce

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Benzenoids / Aryl fluorides
show 12 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Tertiary aliphatic/aromatic amine
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, aminoquinoline, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid (CHEBI:100241)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. [PubMed:12473806]
  4. Lee JK, Lee YS, Park YK, Kim BS: Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol. 2005;49(7):647-53. [PubMed:16034208]
  5. Leavis HL, Willems RJ, Top J, Bonten MJ: High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol. 2006 Mar;44(3):1059-64. [PubMed:16517894]
  6. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. [PubMed:12473806]
  4. Abdelbaqi K, Menard A, Prouzet-Mauleon V, Bringaud F, Lehours P, Megraud F: Nucleotide sequence of the gyrA gene of Arcobacter species and characterization of human ciprofloxacin-resistant clinical isolates. FEMS Immunol Med Microbiol. 2007 Apr;49(3):337-45. [PubMed:17378897]
  5. Taylor DE, Chau AS: Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob Agents Chemother. 1997 Mar;41(3):665-71. [PubMed:9056011]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother. 1992 Apr;36(4):751-6. [PubMed:1323952]
  3. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8. [PubMed:3015015]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Keseru GM: Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. [PubMed:12873512]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P0AES4
Uniprot Name
DNA gyrase subunit A
Molecular Weight
96962.63 Da
References
  1. Hubschwerlen C, Specklin JL, Baeschlin DK, Borer Y, Haefeli S, Sigwalt C, Schroeder S, Locher HH: Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg Med Chem Lett. 2003 Dec 1;13(23):4229-33. [PubMed:14623007]
Kind
Protein
Organism
Staphylococcus aureus
Pharmacological action
Unknown
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P0C1U9
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
91040.465 Da
References
  1. Wiles JA, Song Y, Wang Q, Lucien E, Hashimoto A, Cheng J, Marlor CW, Ou Y, Podos SD, Thanassi JA, Thoma CL, Deshpande M, Pucci MJ, Bradbury BJ: Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1277-81. Epub 2005 Dec 7. [PubMed:16337789]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
Unknown
General Function
Magnesium ion binding
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parE
Uniprot ID
Q59192
Uniprot Name
DNA topoisomerase 4 subunit B
Molecular Weight
73006.17 Da
References
  1. Butler MM, Lamarr WA, Foster KA, Barnes MH, Skow DJ, Lyden PT, Kustigian LM, Zhi C, Brown NC, Wright GE, Bowlin TL: Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother. 2007 Jan;51(1):119-27. Epub 2006 Oct 30. [PubMed:17074800]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
Unknown
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P05653
Uniprot Name
DNA gyrase subunit A
Molecular Weight
92098.19 Da
References
  1. Butler MM, Lamarr WA, Foster KA, Barnes MH, Skow DJ, Lyden PT, Kustigian LM, Zhi C, Brown NC, Wright GE, Bowlin TL: Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother. 2007 Jan;51(1):119-27. Epub 2006 Oct 30. [PubMed:17074800]
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
General Function
Drug transmembrane transporter activity
Specific Function
Multidrug efflux pump that functions probably as a Na(+)/drug antiporter.
Gene Name
mdtK
Uniprot ID
C3T8E2
Uniprot Name
Multidrug resistance protein MdtK
Molecular Weight
49446.52 Da
References
  1. Long F, Rouquette-Loughlin C, Shafer WM, Yu EW: Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli. Antimicrob Agents Chemother. 2008 Sep;52(9):3052-60. doi: 10.1128/AAC.00475-08. Epub 2008 Jun 30. [PubMed:18591276]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
B4YQT9
Uniprot Name
Gyrase A
Molecular Weight
17024.015 Da
References
  1. Karkare S, Chung TT, Collin F, Mitchenall LA, McKay AR, Greive SJ, Meyer JJ, Lall N, Maxwell A: The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action. J Biol Chem. 2013 Feb 15;288(7):5149-56. doi: 10.1074/jbc.M112.419069. Epub 2012 Dec 28. [PubMed:23275348]
Kind
Protein
Organism
Staphylococcus aureus
Pharmacological action
Unknown
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P20831
Uniprot Name
DNA gyrase subunit A
Molecular Weight
99620.34 Da
References
  1. Surivet JP, Zumbrunn C, Rueedi G, Hubschwerlen C, Bur D, Bruyere T, Locher H, Ritz D, Keck W, Seiler P, Kohl C, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Gaertner M, Delers J, Enderlin-Paput M, Boehme M: Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity. J Med Chem. 2013 Sep 26;56(18):7396-415. doi: 10.1021/jm400963y. Epub 2013 Sep 11. [PubMed:23968485]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  2. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  2. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR: The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 1995 Mar;39(3):305-11. [PubMed:7619673]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Drug Interactions & Labeling - FDA [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742]
  2. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41